Kenvue shares fell 2.5% after a US appeals panel signalled that 500 dismissed Tylenol-autism lawsuits may be revived. The development follows comments from Donald Trump suggesting prenatal Tylenol use raises autism risk, claims Kenvue denies. A renewed legal overhang could also complicate Kimberly-Clarks $40 billion takeover bid, with analysts warning of execution risks.